Goldman Sachs’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,776,785
| Closed | -$272M | – | 6916 |
|
|
2025
Q4 | $272M | Buy |
3,776,785
+2,044,316
| +118% | +$132M | 0.03% | 515 |
|
|
2025
Q3 | $75.5M | Buy |
1,732,469
+586,935
| +51% | +$23.7M | 0.01% | 1124 |
|
|
2025
Q2 | $32.5M | Buy |
1,145,534
+360,830
| +46% | +$10.8M | ﹤0.01% | 1681 |
|
|
2025
Q1 | $23.2M | Buy |
784,704
+21,649
| +3% | +$674K | ﹤0.01% | 1896 |
|
|
2024
Q4 | $22.2M | Sell |
763,055
-111,692
| -13% | -$4.67M | ﹤0.01% | 2031 |
|
|
2024
Q3 | $40.2M | Buy |
874,747
+330,696
| +61% | +$14.4M | 0.01% | 1427 |
|
|
2024
Q2 | $22.2M | Buy |
544,051
+28,771
| +6% | +$826K | ﹤0.01% | 1802 |
|
|
2024
Q1 | $13.1M | Buy |
515,280
+161,635
| +46% | +$2.53M | ﹤0.01% | 2225 |
|
|
2023
Q4 | $3.2M | Sell |
353,645
-122,265
| -26% | -$817K | ﹤0.01% | 3553 |
|
|
2023
Q3 | $3.04M | Sell |
475,910
-79,925
| -14% | -$689K | ﹤0.01% | 3415 |
|
|
2023
Q2 | $6.16M | Sell |
555,835
-457,640
| -45% | -$5.74M | ﹤0.01% | 2918 |
|
|
2023
Q1 | $15.6M | Sell |
1,013,475
-105,312
| -9% | -$2.32M | ﹤0.01% | 2023 |
|
|
2022
Q4 | $24.8M | Buy |
1,118,787
+499,887
| +81% | +$7.45M | 0.01% | 1761 |
|
|
2022
Q3 | $10.1M | Buy |
618,900
+435,617
| +238% | +$8.33M | ﹤0.01% | 2493 |
|
|
2022
Q2 | $2.66M | Buy |
183,283
+61,391
| +50% | +$913K | ﹤0.01% | 3790 |
|
|
2022
Q1 | $2.25M | Buy |
121,892
+11,659
| +11% | +$198K | ﹤0.01% | 4155 |
|
|
2021
Q4 | $2.62M | Sell |
110,233
-234,246
| -68% | -$5.59M | ﹤0.01% | 4012 |
|
|
2021
Q3 | $8.48M | Buy |
344,479
+150,618
| +78% | +$3.27M | ﹤0.01% | 2880 |
|
|
2021
Q2 | $4.79M | Sell |
193,861
-171,184
| -47% | -$3.98M | ﹤0.01% | 3378 |
|
|
2021
Q1 | $7.96M | Buy |
365,045
+140,901
| +63% | +$3.45M | ﹤0.01% | 2753 |
|
|
2020
Q4 | $5.72M | Buy |
224,144
+123,026
| +122% | +$3.59M | ﹤0.01% | 2915 |
|
|
2020
Q3 | $2.85M | Sell |
101,118
-51,823
| -34% | -$1.5M | ﹤0.01% | 3319 |
|
|
2020
Q2 | $4.32M | Buy |
+152,941
| New | +$4.41M | ﹤0.01% | 2910 |
|
Other funds holding RNAM
Goldman Sachs's RNAM Position: Q1 2026 in Review
Goldman Sachs sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,776,785 shares — an estimated $272M sold.
Goldman Sachs first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $272M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Goldman Sachs reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 3,776,785 Avidity Biosciences shares in Q1 2026, an estimated $272M.
- Goldman Sachs first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
- Goldman Sachs's Avidity Biosciences position peaked at $272M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.